AR107973A1 - 6-hidroxi-4-oxo-1,4-dihidropirimidin-5-carboxamidas como agonista de apj - Google Patents
6-hidroxi-4-oxo-1,4-dihidropirimidin-5-carboxamidas como agonista de apjInfo
- Publication number
- AR107973A1 AR107973A1 ARP170100736A ARP170100736A AR107973A1 AR 107973 A1 AR107973 A1 AR 107973A1 AR P170100736 A ARP170100736 A AR P170100736A AR P170100736 A ARP170100736 A AR P170100736A AR 107973 A1 AR107973 A1 AR 107973A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- independently selected
- case
- cr7r7
- alkyl
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- 125000000623 heterocyclic group Chemical group 0.000 abstract 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 4
- 125000004452 carbocyclyl group Chemical group 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 229910052757 nitrogen Inorganic materials 0.000 abstract 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 229910052794 bromium Inorganic materials 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 229910052801 chlorine Inorganic materials 0.000 abstract 2
- 229910052731 fluorine Inorganic materials 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 125000006706 (C3-C6) carbocyclyl group Chemical group 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662312780P | 2016-03-24 | 2016-03-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR107973A1 true AR107973A1 (es) | 2018-07-04 |
Family
ID=58464691
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170100736A AR107973A1 (es) | 2016-03-24 | 2017-03-23 | 6-hidroxi-4-oxo-1,4-dihidropirimidin-5-carboxamidas como agonista de apj |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US10106528B2 (enExample) |
| EP (1) | EP3433247B1 (enExample) |
| JP (1) | JP6716711B2 (enExample) |
| KR (1) | KR102433280B1 (enExample) |
| CN (1) | CN109195963B (enExample) |
| AR (1) | AR107973A1 (enExample) |
| AU (1) | AU2017238504B2 (enExample) |
| BR (1) | BR112018068341A2 (enExample) |
| CA (1) | CA3018346A1 (enExample) |
| CL (1) | CL2018002671A1 (enExample) |
| CO (1) | CO2018011105A2 (enExample) |
| EA (1) | EA037162B1 (enExample) |
| ES (1) | ES2895124T3 (enExample) |
| IL (1) | IL261904B (enExample) |
| MA (1) | MA43761A (enExample) |
| MX (1) | MX379088B (enExample) |
| MY (1) | MY189454A (enExample) |
| PE (1) | PE20181777A1 (enExample) |
| SG (1) | SG11201808163WA (enExample) |
| TW (1) | TWI744301B (enExample) |
| UY (1) | UY37169A (enExample) |
| WO (1) | WO2017165640A1 (enExample) |
| ZA (1) | ZA201806356B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20191327T1 (hr) | 2015-06-03 | 2019-11-01 | Bristol Myers Squibb Co | 4-hidroksi-3-(heteroaril)piridin-2-on apj agonisti za primjenju u liječenju kardiovaskularnih poremećaja |
| US10392347B2 (en) | 2015-10-14 | 2019-08-27 | Bristol-Myers Squibb Company | 2,4-dihydroxy-nicotinamides as APJ agonists |
| AR106948A1 (es) | 2015-12-04 | 2018-03-07 | Bristol Myers Squibb Co | Agonistas del receptor de apelina y método de uso |
| EP3390400B1 (en) | 2015-12-16 | 2021-01-20 | Bristol-Myers Squibb Company | Heteroarylhydroxypyrimidinones as agonists of the apj receptor |
| MY189454A (en) * | 2016-03-24 | 2022-02-14 | Bristol Myers Squibb Co | 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists |
| EP3452466B1 (en) | 2016-05-03 | 2020-08-12 | Amgen Inc. | Heterocyclic triazole compounds as agonists of the apj receptor |
| KR102521955B1 (ko) | 2016-06-14 | 2023-04-13 | 브리스톨-마이어스 스큅 컴퍼니 | Apj 수용체 효능제로서의 4-히드록시-3-술포닐피리딘-2(1h)-온 |
| WO2017218633A1 (en) | 2016-06-14 | 2017-12-21 | Bristol-Myers Squibb Company | 6-hydroxy-5-(phenyl/heteroarylsulfonyl)pyrimidin-4(1h)-one as apj agonists |
| KR102521956B1 (ko) | 2016-10-14 | 2023-04-14 | 브리스톨-마이어스 스큅 컴퍼니 | 3-술포닐-5-아미노피리딘-2,4-디올 apj 효능제 |
| EP3541803B1 (en) | 2016-11-16 | 2020-12-23 | Amgen Inc. | Triazole pyridyl compounds as agonists of the apj receptor |
| US10906890B2 (en) | 2016-11-16 | 2021-02-02 | Amgen Inc. | Triazole phenyl compounds as agonists of the APJ receptor |
| US11046680B1 (en) | 2016-11-16 | 2021-06-29 | Amgen Inc. | Heteroaryl-substituted triazoles as APJ receptor agonists |
| EP3541802B1 (en) | 2016-11-16 | 2025-01-01 | Amgen Inc. | Alkyl substituted triazole compounds as agonists of the apj receptor |
| EP3541792B1 (en) | 2016-11-16 | 2020-12-23 | Amgen Inc. | Triazole furan compounds as agonists of the apj receptor |
| WO2018093577A1 (en) | 2016-11-16 | 2018-05-24 | Amgen Inc. | Cycloalkyl substituted triazole compounds as agonists of the apj receptor |
| WO2019089335A1 (en) | 2017-11-03 | 2019-05-09 | Amgen Inc. | Fused triazole agonists of the apj receptor |
| EP3788037A1 (en) | 2018-05-01 | 2021-03-10 | Amgen Inc. | Substituted pyrimidinones as agonists of the apj receptor |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH602664A5 (en) * | 1973-06-14 | 1978-07-31 | Sandoz Ag | 2-Tert. amino-alkylamino-pyrimidine derivs. |
| GB2263639A (en) | 1992-01-28 | 1993-08-04 | Merck & Co Inc | Substituted pyrimidinones as neurotensin antagonists |
| AU744518B2 (en) | 1996-07-01 | 2002-02-28 | Dr. Reddy's Laboratories Limited | Novel heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases |
| CA2416248A1 (en) | 2000-07-18 | 2002-01-24 | Neurogen Corporation | 5-substituted 2-aryl-4-pyrimidinones |
| TW200300349A (en) | 2001-11-19 | 2003-06-01 | Sankyo Co | A 4-oxoqinoline derivative |
| US7166595B2 (en) | 2002-05-09 | 2007-01-23 | Cytokinetics, Inc. | Compounds, methods and compositions |
| JP2005530806A (ja) | 2002-05-23 | 2005-10-13 | メルク エンド カムパニー インコーポレーテッド | 有糸分裂キネシン阻害薬 |
| JP2004339159A (ja) | 2003-05-16 | 2004-12-02 | Sankyo Co Ltd | ４−オキソキノリン誘導体を含有する医薬組成物 |
| WO2005026148A1 (en) | 2003-09-08 | 2005-03-24 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
| JP2007510652A (ja) | 2003-11-03 | 2007-04-26 | サイトキネティクス・インコーポレーテッド | ピリミジン−４−オン化合物、組成物、および方法 |
| WO2005060654A2 (en) | 2003-12-19 | 2005-07-07 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
| US7732613B2 (en) | 2005-09-14 | 2010-06-08 | Bristol-Myers Squibb Company | Met kinase inhibitors |
| WO2007037543A1 (ja) | 2005-09-29 | 2007-04-05 | Banyu Pharmaceutical Co., Ltd. | ビアリールアミド誘導体 |
| US7728017B2 (en) | 2005-11-30 | 2010-06-01 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-Met and uses thereof |
| WO2007124397A2 (en) | 2006-04-21 | 2007-11-01 | Trustees Of Boston University | Ionic viscoelastics and viscoelastic salts |
| WO2008052861A2 (de) | 2006-10-10 | 2008-05-08 | Proionic Production Of Ionic Substances Gmbh & Co Keg | Verfahren zur herstellung von 1,3 -hetero-aromatischen carbonaten |
| WO2008052863A2 (de) | 2006-10-10 | 2008-05-08 | Proionic Production Of Ionic Substances Gmbh & Co Keg | Verfahren zur umsetzung von 1,3-hetero-aromatischen 2-carboxylaten mit wasser |
| TW200845994A (en) * | 2007-01-12 | 2008-12-01 | Smithkline Beecham Corp | N-substituted glycine derivatives: prolyl hydroxylase inhibitors |
| CA2676173A1 (en) | 2007-02-16 | 2008-08-28 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors |
| EP3042660A3 (en) | 2008-04-15 | 2016-10-26 | RFS Pharma, LLC. | Nucleoside derivatives for treatment of caliciviridae infections, including norovirus infections |
| EP2379684A2 (de) | 2008-12-22 | 2011-10-26 | Basf Se | Mischungen hydrophober und hydrophiler ionischer flüssigkeiten und ihre verwendung in flüssigkeitsringverdichtern |
| CA2762680C (en) | 2009-05-21 | 2018-04-17 | Chlorion Pharma, Inc. | Methyl sulfanyl pyrmidmes useful as antiinflammatories, analgesics, and antiepileptics |
| WO2012020742A1 (ja) | 2010-08-10 | 2012-02-16 | 塩野義製薬株式会社 | 新規複素環誘導体およびそれらを含有する医薬組成物 |
| JP2014522570A (ja) | 2011-05-31 | 2014-09-04 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 電解質配合物 |
| AU2012265219B2 (en) | 2011-05-31 | 2017-02-16 | Merck Patent Gmbh | Compounds containing hydrido-tricyano-borate anions |
| WO2014004676A1 (en) | 2012-06-26 | 2014-01-03 | Ironwood Pharmaceuticals, Inc. | Use of faah inhibitors as neuroprotective agents in the cns |
| DE102012021452A1 (de) | 2012-10-31 | 2014-04-30 | Merck Patent Gmbh | Salze mit Trihydroperfluoralkoxybutansulfonat- oder Trihydroperfluoralkoxypropansulfonat-Anion |
| KR20150135332A (ko) | 2013-03-14 | 2015-12-02 | 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 | 미토콘드리아 알데히드 탈수소효소-2 조절인자들 및 이들의 사용 방법 |
| PE20160664A1 (es) | 2013-06-27 | 2016-07-09 | Pfizer | Compuestos heteroaromaticos y su uso como ligandos d1 de dopamina |
| WO2014207100A1 (en) | 2013-06-27 | 2014-12-31 | Basf Se | A process for coating paper with cellulose using a solution containing cellulose |
| CA2930343C (en) | 2013-11-29 | 2021-06-08 | Proionic Gmbh | Method for curing an adhesive using microwave irradiation |
| US10570128B2 (en) * | 2014-05-28 | 2020-02-25 | Sanford Burnham Prebys Medical Discovery Institute | Agonists of the apelin receptor and methods of use thereof |
| WO2015188073A1 (en) * | 2014-06-06 | 2015-12-10 | Research Triangle Institute | Apelin receptor (apj) agonists and uses thereof |
| WO2016074757A1 (de) | 2014-11-11 | 2016-05-19 | Merck Patent Gmbh | Verfahren zur herstellung von mono- und bis(perfluoralkyl)fluorophosphatsalzen und deren säuren |
| JP6358639B2 (ja) | 2015-04-24 | 2018-07-18 | 塩野義製薬株式会社 | ６員複素環誘導体およびそれらを含有する医薬組成物 |
| MA42145B1 (fr) | 2015-05-20 | 2020-05-29 | Amgen Inc | Triazoles agonistes du récepteur apj |
| HRP20191327T1 (hr) * | 2015-06-03 | 2019-11-01 | Bristol Myers Squibb Co | 4-hidroksi-3-(heteroaril)piridin-2-on apj agonisti za primjenju u liječenju kardiovaskularnih poremećaja |
| KR101711744B1 (ko) | 2015-07-16 | 2017-03-02 | 경희대학교 산학협력단 | 옥사디아졸 유도체, 이의 제조방법 및 이를 포함하는 전자수송층 |
| US10392347B2 (en) | 2015-10-14 | 2019-08-27 | Bristol-Myers Squibb Company | 2,4-dihydroxy-nicotinamides as APJ agonists |
| US10626096B2 (en) | 2015-11-24 | 2020-04-21 | Sanford Burnham Prebys Medical Discovery Institute | Azole derivatives as apelin receptor agonist |
| AR106948A1 (es) | 2015-12-04 | 2018-03-07 | Bristol Myers Squibb Co | Agonistas del receptor de apelina y método de uso |
| EP3390400B1 (en) | 2015-12-16 | 2021-01-20 | Bristol-Myers Squibb Company | Heteroarylhydroxypyrimidinones as agonists of the apj receptor |
| MY189454A (en) * | 2016-03-24 | 2022-02-14 | Bristol Myers Squibb Co | 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists |
| WO2017218633A1 (en) | 2016-06-14 | 2017-12-21 | Bristol-Myers Squibb Company | 6-hydroxy-5-(phenyl/heteroarylsulfonyl)pyrimidin-4(1h)-one as apj agonists |
| KR102521955B1 (ko) | 2016-06-14 | 2023-04-13 | 브리스톨-마이어스 스큅 컴퍼니 | Apj 수용체 효능제로서의 4-히드록시-3-술포닐피리딘-2(1h)-온 |
-
2017
- 2017-03-23 MY MYPI2018703358A patent/MY189454A/en unknown
- 2017-03-23 TW TW106109801A patent/TWI744301B/zh not_active IP Right Cessation
- 2017-03-23 WO PCT/US2017/023801 patent/WO2017165640A1/en not_active Ceased
- 2017-03-23 AU AU2017238504A patent/AU2017238504B2/en not_active Ceased
- 2017-03-23 BR BR112018068341A patent/BR112018068341A2/pt not_active Application Discontinuation
- 2017-03-23 PE PE2018001835A patent/PE20181777A1/es unknown
- 2017-03-23 EA EA201892123A patent/EA037162B1/ru not_active IP Right Cessation
- 2017-03-23 AR ARP170100736A patent/AR107973A1/es not_active Application Discontinuation
- 2017-03-23 MA MA043761A patent/MA43761A/fr unknown
- 2017-03-23 EP EP17715361.6A patent/EP3433247B1/en active Active
- 2017-03-23 SG SG11201808163WA patent/SG11201808163WA/en unknown
- 2017-03-23 CA CA3018346A patent/CA3018346A1/en active Pending
- 2017-03-23 KR KR1020187030255A patent/KR102433280B1/ko active Active
- 2017-03-23 MX MX2018011194A patent/MX379088B/es unknown
- 2017-03-23 ES ES17715361T patent/ES2895124T3/es active Active
- 2017-03-23 CN CN201780031787.XA patent/CN109195963B/zh active Active
- 2017-03-23 JP JP2018549910A patent/JP6716711B2/ja active Active
- 2017-03-24 US US15/468,230 patent/US10106528B2/en active Active
- 2017-03-24 UY UY0001037169A patent/UY37169A/es unknown
-
2018
- 2018-09-06 US US16/122,975 patent/US10590113B2/en active Active
- 2018-09-20 IL IL261904A patent/IL261904B/en active IP Right Grant
- 2018-09-21 CL CL2018002671A patent/CL2018002671A1/es unknown
- 2018-09-21 ZA ZA2018/06356A patent/ZA201806356B/en unknown
- 2018-10-17 CO CONC2018/0011105A patent/CO2018011105A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR107061A1 (es) | Heteroarilhidroxipirimidinonas como agonistas del receptor de apj | |
| AR106948A1 (es) | Agonistas del receptor de apelina y método de uso | |
| AR104884A1 (es) | Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj | |
| AR110405A1 (es) | Compuestos | |
| AR098414A1 (es) | PIPERAZINAS DE PIRAZOLO SUSTITUIDO COMO INHIBIDORES DE CASEÍNA QUINASA 1 d/e | |
| AR100033A1 (es) | Compuestos y composiciones para inhibir la actividad de shp2 | |
| AR094299A1 (es) | Derivados de ftalazin-1(2h)-ona sustituidos | |
| AR120338A1 (es) | Piridazinonas como inhibidores de parp7 | |
| AR104176A1 (es) | Inhibidores de ido (indolamina-2,3-dioxigenasa) | |
| AR103990A1 (es) | Ureas cíclicas como inhibidoras de rock | |
| AR099379A1 (es) | Compuestos tricíclicos como agentes antineoplásicos | |
| AR109349A1 (es) | Compuestos y usos | |
| AR107912A1 (es) | Inhibidores de ret | |
| AR096788A1 (es) | Compuestos tricíclicos de carboxamida como inhibidores potentes de rock | |
| AR108838A1 (es) | Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa | |
| AR113929A1 (es) | Compuestos heterocíclicos | |
| AR092349A1 (es) | Imidazotriazincarbonitrilos utiles como inhibidores de quinasa | |
| AR094300A1 (es) | Derivados de quinolonas | |
| AR097082A1 (es) | Compuestos terapéuticamente activos y sus métodos de uso | |
| AR107321A1 (es) | Compuestos antiproliferativos, y sus composiciones farmacéuticas y usos | |
| AR110789A1 (es) | Compuestos moduladores del receptor de hidrocarburos de arilo (ahr) | |
| AR098666A1 (es) | Compuestos de biarilacetamida y sus métodos de uso | |
| AR094702A1 (es) | Compuestos de azabencimidazol | |
| AR110790A1 (es) | Compuestos moduladores del receptor de hidrocarburos de arilo (ahr) | |
| AR100807A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |